drugset / Trial / NCT03792503

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

NCT03792503

Phase 4 Withdrawn Xinqiao Hospital of Chongqing
NaSingle-groupOpen-labelTreatment

Summary

In order to further improve the therapeutic efficacy of advanced no-squamous non-small cell lung cancer patients, improve the life cycle, this study will take the standard after treatment pemetrexed combined other anti-angiogenesis drugs to maintain as the direction, so as to provide more over the evidence for the treatment of advanced NSCLC.

Timeline

Start
2019-02
Primary completion
2020-02
Completion
2022-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Pemetrexed Small molecule 500 mg/m2
Subject Rivoceranib Small molecule 500 mg Oral